Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia
Haemophilia · 2023
DOI: 10.1111/hae.14814 ↗Kurz gefasst
Leserbrief in der Zeitschrift Haemophilia, 2023. Verfasst von Xiaohong Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Development China, Pfizer Investment Co. Ltd., Beijing, China. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Development China, Pfizer Investment Co. Ltd., Beijing, China.
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
- Pfizer (China) R&D Center, Shanghai, China.
- Pfizer Healthcare India Private Ltd., Chennai, India.
- Pfizer Inc, Groton, Connecticut, USA.
- Pfizer Inc, Collegeville, Pennsylvania, USA.
ORCID-Profile: Xiaohong Sun, Renchi Yang
Förderung
- Pfizer
Zitieren
APA
Sun, X., Liu, W., Luo, B., Ma, D., Kalluru, H., Zhou, Y., Li, J., Peng, A., Liu, Y., Tong, X., Sun, L., Teeter, J., Raje, S., & Yang, R. (2023). Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia. Haemophilia. https://doi.org/10.1111/hae.14814
Vancouver
Sun X, Liu W, Luo B, Ma D, Kalluru H, Zhou Y, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia. Haemophilia. 2023. doi:10.1111/hae.14814
BibTeX
@article{Sun2023,
author = {Sun, Xiaohong and Liu, Wei and Luo, Binyu and Ma, Dongwei and Kalluru, Hindu and Zhou, Yangmei and Li, Jin and Peng, Ao and Liu, Yuwang and Tong, Xin and Sun, Lei and Teeter, John and Raje, Sangeeta and Yang, Renchi},
title = {Safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of marstacimab in Chinese participants with severe haemophilia},
journal = {Haemophilia},
year = {2023},
doi = {10.1111/hae.14814}
}
EUVIMED